Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit
cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at
opm.gov.
Longitudinal microbiome-host interactions and clinical outcomes in drug-resistant tuberculosis patients
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Emerging Global Leader
Project Information in NIH RePORTER
Longitudinal microbiome-host interactions and clinical outcomes in drug-resistant tuberculosis patients
Principal Institution
Stellenbosch University Tygerberg Campus
Principal Investigator(s) (PI)
Naidoo, Charissa Camille
Project Contact Information
Email:
ccnaidoo@sun.ac.za
Year(s) Awarded
2022 –2027
Country
South Africa
Project Description
Host microbial communities (microbiota) profoundly affect our health and are changed by antibiotics. However, microbial disturbances during treatment for drug-resistant tuberculosis (a leading cause of death for which tens of millions of antibiotics doses are prescribed annually) remain uncharacterized and may help explain clinical outcomes and long-term overall health, including post-treatment sequalae.
Through leveraging of an already funded observational cohort of drug-resistant TB patients on treatment, we will evaluate microbiota changes before, during, and after treatment (including how these changes correspond to drug absorption), how specific taxa correspond to microbial metabolic end-products, and the microbiota’s association with treatment response. This program of work will also, through structured and dedicated career development, strengthen South African analytical capacity in the microbiome and inform future clinical trials that modulate the microbiome in the context of TB.
Related World Regions / Countries
Related Global Health Research Topics